Lisa Denison is the new leader of marketing at Paradigm Spine, LLC. Denison, now the company’s Vice President of Marketing, and has held positions at Sulzer Orthopedics, Abbott Spine, and LDR Spine.
Lisa Denison: New VP of Marketing at Paradigm Spine

As Paradigm wrote in its March 26, 2018 news release, “…Denison has worked in orthopedic and spine marketing and medical education for more than 20 years, including 14 years dedicated to implantable spinal devices.”
“Prior experience includes positions at Sulzer Orthopedics, Abbott Spine, and LDR Spine, serving as the marketing lead on more than eight U.S. and four international medical device commercializations, four of which involved class III devices that underwent full IDE [investigational device exemption] clinical trial and PMA [premarket approval] processes. Ms. Denison earned her B.S. in Kinesiology/Biology from the University of North Texas and her M.B.A. from Baylor University.”
Lisa Denison commented to OTW, “Many years of marketing and education experience with arthroplasty, both in total joint replacement and spine, have prepared me the most for my new role with Paradigm Spine. Over the years, I’ve gained a deep understanding of the various fusion and motion treatment options available to spine patients today.”
“I’ve been fortunate to learn from great surgeons, scientists, and real patients how motion preservation can be a compelling and effective solution to degenerative spine conditions. After studying the technology and ample research behind coflex, I quickly became convinced of its merits and untapped potential. The reality is that spine patients are still unnecessarily fused today, and this is something we can and should change. I am committed to leveraging my prior experience and modern marketing strategies to responsibly get the information about coflex to the surgeons that can perform the surgery, and the indicated patients that deserve access to superior treatments.”

Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.